Summary
Intensive doses of carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support were given to four patients with advanced melanoma. Three developed clinically diagnosed, severe venoocclusive liver disease, which was fatal in two cases. The dose of carboplatin (450 mg/m2) was comparable with that used in ambulatory regimens. At the doses and schedule employed, this three-drug combination produced excessive hepatic toxicity. Caution is suggested when giving carboplatin in combination with intensive doses of other chemotherapeutic agents with known hepatotoxic potential.
This is a preview of subscription content, log in via an institution to check access.
References
Calvert AM, Harland SJ, Newell DR (1982) Early clinical studies withcis-diammine-1,1-cyclobutanedicarboxylatoplatinum (II). Cancer Chemother Pharmacol 9: 140–147
Harrap KH, Jones M, Wilkinson CR, Clink H, Sparrow S, Mitchley B, Clarke S, Veasey A (1980) Antitumor, toxic and biochemical properties of cisplatin and other platinum complexes. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin, current advances and new developments. Academic Press, New York, pp 193–212
Jones RB, Shpall EJ, Shogan J, Moore J, Gockerman J, Peters WP (1988) AFM induction chemotherapy followed by intensive consolidation with autologous bone marrow (ABM) support for advanced breast cancer (abstract). Proc Am Assoc Clin Oncol 8: 8
McDonald GB, Sharma P, Matthews DE, (1981) Venoocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 4: 116–122
Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, Anderson J, Anderson K, Kruskall MS, Schnipper L, Frei E III (1986) High-dose combination alkylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol 4: 646–654
Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO (1988) High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6: 1368–1376
Rollins BJ (1986) Hepatic veno-occlusive disease. Am J Med 81: 297–306
Shea TC, Flaherty M, Elias A, Eder JP, Antman K, Begg C, Schnipper L, Frei E III, Henner WD (1989) A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 7: 651–661
Author information
Authors and Affiliations
Additional information
Supported in part by National Institutes of Health grant CA-14236-16
Rights and permissions
About this article
Cite this article
Jones, R.B., Shpall, E.J., Ross, M. et al. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. Cancer Chemother Pharmacol 26, 155–156 (1990). https://doi.org/10.1007/BF02897264
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02897264